Ares Trading S.a.

Applied Research Systems Ars Holding N.v.

Laboratoires Serono S.a.

Mara Rossi

Thierry Ziegler

Gianfranco Paradisi

Laura Scaglia

Dina G Fischer

Anna Rita Pezzotti

Alain Bernard

Paul Ducommun

Wolf Palinsky

Antonello Datola

Sabrina Fiumi

Laure Valognes

Anna R Pezzotti

Antonio Datola

The present invention provides a composition comprising an interferon-beta (IFN-beta) protein of which at least 80% is deamidated, a deamidated IFN-beta 1a protein, methods of producing deamidated proteins, and therapeutic uses of such compositions and deamidated IFN-beta 1a proteins.

IFN beta protein analogs

The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.

Process for the preparation of glycosylated interferon beta

The invention relates to a method for purifying a glycoprotein, preferably FSH or a FSH mutant, comprising the steps of subjecting a liquid containing FSH or a FSH mutant to: (1) a dye affinity chromatography; (2) a weak anion exchange chromatography; (3) a hydrophobic interaction chromatography; and (4) a strong anion exchange chromatography; which may be carried out in any order.

Method for purifying FSH or a FSH mutant

The invention relates to the analytical determination of poloxamers in a liquid protein sample.

Method for the quantitative determination of poloxamers

The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid comprising hydrophobic charge-induction chromatography.

Process for the purification of IL-18 binding protein

The invention provides a method for purifying recombinant FSH.

Method for purifying FSH

A process for the purification of recombinant human Chorionic Gonadotropin (hCG) from a sample of crude recombinant hCG in the supernatant of CHO cells comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography is performed twice and the final use of a size exclusion chromatography allows the purification from any residual traces of contaminants. The specific bioactivity of the highly purified hCG obtained form the process is particularly high, amounting to about 25,000 IU/mg.

Process of purification of hCG and recombinant hCG purified by that method

A process for the purification of recombinant human Luteinizing Hormone (LH) from a sample of crude recombinant LH in the supernatant of CHO cells comprises the combined use of the ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography and the reverse phase HPLC are performed twice and the final use of a gel permeation column allows the purification from any residual traces of contaminants. The specific bioactivity of the highly purified LH obtained from the process is particularly high, amounting to 25,000 IU/mg.

Growing community of inventors

Rome, Italy

Mara Rossi